Infectious Diseases Search
Infectious Diseases Infectious Diseases
warts%20-%20cutaneous
WARTS - CUTANEOUS
Cutaneous warts, also called verrucae, are benign proliferations of skin caused by human papillomavirus (HPV).
Most common warts on the hands and feet are due to HPV types 1, 2, 4, 27 & 57.
HPV is usually transmitted by contact with skin of an infected individual or by transmission of virus living in warm moist environment.
Autoinoculation may occur from traumatizing lesions by biting or scratching.
Incubation period is unknown but may range from months to years.

Warts - Cutaneous Drug Information

Drug Information

Indication: Squamous cell carcinoma of skin, head, neck & oesophagus, larynx, penis & uterine cervix, bronchus. Ch...

Indication: Alone or in combination for palliative treatment of malignant tumours, particularly of breast, colon or rectum...

Duofilm
lactic acid + salicylic acid

Indication: Warts, corns & calluses.

Indication: Corns, warts & calluses.

Verrumal
dimethylsulfoxide + fluorouracil + salicylic acid

Indication: Common, flat juvenile & plantar warts.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
COVID-19 pandemic causes drop in cardiovascular diagnostic testing
16 Jan 2021
Diagnosis of heart diseases has abruptly and significantly decreased across the globe due to the coronavirus disease 2019 (COVID-19) pandemic, especially affecting poorer countries, reveals a study.
Evidence-based intervention fails to reduce haemodialysis catheter-related bloodstream infection
Roshini Claire Anthony, 01 Dec 2020

An evidence-based, multifaceted intervention aimed at reducing haemodialysis catheter-related bloodstream infections (HD-CRBSIs) failed to improve this outcome, results of the REDUCCTION* trial showed.
Anticoagulant for COVID-19: Higher dose=better survival?
Pearl Toh, Yesterday
While it is well known that COVID-19 illness is associated with coagulopathy, the optimal anticoagulation strategy remains elusive, and two studies presented at the ASH 2020 Congress further add to the growing debate on the appropriate anticoagulant dose for hospitalized patients with COVID-19.